AI MARKET SCANNING

Corvus Pharmaceuticals Inc

📅 Next Catalyst: Nov 03, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Pharmaceuticals Major
AVG HISTORICAL GAP +2.32%
MAX GAP RECORD +14.61%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CRVS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 03, 2026 Earnings Release 2026-11-03 (AFTER CLOSE (21:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE)
-6.91%
May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE)
+1.51%
Mar 12, 2026 Earnings Release 2026-03-12 (AFTER CLOSE)
-1.66%
Nov 04, 2025 Earnings Release 2025-11-04 (AFTER CLOSE)
-1.31%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
+1.45%
May 07, 2025 Earnings Release 2025-05-07 (AFTER CLOSE)
-0.31%
Nov 12, 2024 Earnings Release 2024-11-12 (AFTER CLOSE)
+14.61%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.2%
Bullish Gaps (7)
Bearish Gaps (4)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CRVS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗